Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Interim Management Statement

7 Jun 2013 16:43

RNS Number : 6084G
Maven Income & Growth VCT 4 PLC
07 June 2013
 



Maven Income and Growth VCT 4 PLC

 

Interim Management Statement

 

 

 

1. Net Asset Value

 

·; Ordinary share NAV Total Return since launch of 121.54p per share and NAV of 94.2p at 3 April 2013.

 

·; C Ordinary share NAV of 100.0p at 3 April 2013.

 

The NAVs shown above are unaudited and reflect the closing bid prices of quoted securities and the Directors' valuations of unlisted investments as at 3 April 2013, which was the calculation date for the recent merger with Ortus VCT, adjusted for any material developments within the portfolios since that date.

 

 

2. Investments and disposals

 

During the period ended 3 April 2013, the Ordinary share portfolio invested £1,210,000 in seven private equity investments. During the same period, disposals generated aggregate gains on disposal of £424,028 from investments with a cost of £216,343.

 

The S share portfolio invested £549,000 in six private equity investments during the same period, and generated aggregate gains on disposal of £3,503 from investments with a cost of £41,444.  

 

There were no other material transactions during the period under review. 

 

After the end of the period under review, investments totalling £2,019,000 were made in six unlisted companies and gains totalling £433,427 were realised from investments with a cost of £669,168.

 

 

3. Merger

 

On 3 April 2013, the Company merged with Ortus VCT in a s.110 transaction. The financial impact of the merger was set out in the annual report for the year ended 31 December 2012, particularly in Note 19 to the Financial Statements.

 

 

The Board is not aware of any other events or transactions that have taken place between 3 April 2013 and the date of publication of this statement which would have had a material impact on the financial position of the Company.

 

Issued on behalf of the Board

Maven Capital Partners UK LLP, Secretary

 

7 June 2013

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUBSVROUANRAR
Date   Source Headline
20th May 202610:12 amRNSAdmission of Further Securities to Trading
15th May 202610:45 amRNSDirector/PDMR Shareholding
15th May 202610:41 amRNSIssue of Equity - Dividend Investment Scheme
14th May 20265:22 pmRNSTransaction in Own Shares
12th May 20263:37 pmRNSUnaudited NAV - Dividend Investment Scheme
7th May 20261:45 pmRNSResult of AGM
30th Apr 202610:58 amRNSAdmission of Further Securities to Trading
29th Apr 202612:29 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:27 amRNSAdmission of Further Securities to Trading
14th Apr 202611:09 amRNSIssue of Equity
10th Apr 202612:02 pmRNSUnaudited Net Asset Value
8th Apr 20269:33 amRNSAdmission of Further Securities to Trading
25th Mar 20263:51 pmRNSTransaction in Own Shares
25th Mar 202610:55 amRNSAdmission of Further Securities to Trading
24th Mar 202612:11 pmRNSIssue of Equity
19th Mar 20264:21 pmRNSUnaudited NAV and Proposed Final Dividend
18th Feb 20264:58 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202610:54 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:07 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:52 amRNSDirector/PDMR Shareholding
16th Jan 20269:44 amRNSIssue of Equity
15th Jan 202610:36 amRNSDirector/PDMR Shareholding
15th Jan 202610:35 amRNSDirector/PDMR Shareholding
15th Jan 20269:55 amRNSIssue of Equity
14th Jan 20262:39 pmRNSUnaudited NAV - Dividend Investment Scheme
13th Jan 202612:10 pmRNSUnaudited Net Asset Value
4th Dec 202510:35 amRNSSecond Interim Dividend
18th Nov 20253:48 pmRNSTransaction in Own Shares
14th Nov 20259:31 amRNSNet Asset Value(s)
13th Nov 20254:53 pmRNSResult of General Meeting
2nd Oct 20254:42 pmRNSPublication of a Prospectus
29th Aug 20257:00 amRNSDirector/PDMR Shareholding
29th Aug 20257:00 amRNSIssue of Equity
29th Aug 20257:00 amRNSHalf-year Report
20th Aug 20252:14 pmRNSStatement re Dividend Investment Scheme
31st Jul 20254:42 pmRNSTransaction in Own Shares
16th Jul 202510:18 amRNSStatement re Unaudited NAV and Interim Dividend
16th Jul 20257:08 amRNSStatement re Offer for Subscription
21st May 20254:44 pmRNSTransaction in Own Shares
16th May 20259:30 amRNSDirector/PDMR Shareholding
16th May 20259:26 amRNSIssue of Equity - Dividend Investment Scheme
9th May 20251:53 pmRNSStatement re Dividend Investment Scheme
9th May 202510:03 amRNSNet Asset Value(s)
8th May 20251:43 pmRNSResult of AGM
6th May 202511:55 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.